查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2002821

非類固醇消炎劑市場：2026-2032年全球市場預測（依藥物類別、劑型、給藥途徑、處方狀態、上市方式、病患群體、適應症​​、最終用戶和分銷管道分類）

Non-steroidal Anti-inflammatory Drugs Market by Drug Class, Formulation, Route Of Administration, Prescription Status, Release Type, Patient Group, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非類固醇消炎劑(NSAID) 市場價值將達到 246.2 億美元，到 2026 年將成長至 262.2 億美元，到 2032 年將達到 388.1 億美元，複合年成長率為 6.71%。

主要市場統計數據
基準年 2025 246.2億美元
預計年份：2026年 262.2億美元
預測年份：2032年 388.1億美元
複合年成長率 (%) 6.71%

對影響非類固醇消炎劑。

非類固醇消炎劑) 在臨床實踐和消費者自我護理中繼續發揮核心作用，這主要歸因於全球持續存在的疼痛、發炎和慢性肌肉骨骼疾病負擔。本文概述了 NSAIDs 領域不斷演變的現狀，重點闡述了患者期望、監管審查和供應鏈壓力如何相互交織，並重塑產品開發和分銷趨勢。

技術進步、不斷變化的法規以及患者期望的變化，正在如何重塑非類固醇抗發炎藥領域的競爭策略和產品創新？

在技​​術進步、監管政策調整和患者用藥行為變化的推動下，非類固醇消炎劑）市場格局正經歷著變革性的變化。新興的數位療法和遠端醫療正在改變醫療服務的提供地點和決策流程，並為教育和製劑管理創造了新的切入點。同時，藥物警戒和真實世界數據（REW）收集的進步正在加強安全性評估，並影響附加檔和製劑指南的更新。

評估美國累積關稅調整對供應鏈採購、成本管理和商業性定位的營運和策略影響。

到2025年，美國累積關稅調整已給整個醫藥供應鏈帶來巨大的成本壓力，影響採購決策、定價策略和業務永續營運。關稅帶來的成本上漲波及整個價值鏈，迫使製造商和經銷商調整供應商結構、協商修改供應商合約並尋找替代原料，以維持利潤率和供應的連續性。

以細分市場主導的洞察，將分銷管道、給藥途徑、藥物類別、劑型和最終用戶趨勢與策略決策點連結起來。

一套精細的市場細分框架揭示了臨床偏好、分銷管道經濟效益和製劑選擇之間的交集，突顯了影響產品市場競爭力和滲透率的因素。基於分銷管道，該市場研究將藥物分為非處方藥 (OTC) 和處方藥，並著重分析了不同的需求因素：消費者對自我護理的重視程度影響非處方藥的滲透率，而臨床指南和報銷制度則決定了處方藥的使用。基於給藥途徑，該市場研究將藥物分為口服、注射和外用製劑，並重點闡述了給藥途徑如何影響安全性監測、患者依從性和製劑研發重點。

區域分析解釋了區域法規結構、支付方趨勢和醫療保健模式如何推動世界各地不同的策略。

區域趨勢持續影響非類固醇抗發炎藥物的監管方式、報銷管道和應用模式，因此，針對特定區域的策略對於商業性成功至關重要。在美洲，相關人員必須應對支付主導的准入控制、整合的分銷網路以及消費者對非處方止痛藥的高度依賴等複雜因素，這就需要建立相應的證據和價值溝通機制。在歐洲、中東和非洲，不同司法管轄區的法規結構和醫療保健融資模式存在顯著差異，因此需要製定差異化的產品註冊策略和針對特定區域的證據包裝，以應對不同的標準和採購流程。

為了增強競爭優勢，我們優先考慮以供應可靠性、產品差異化和基於證據的定位為重點的公司層級策略。

非類固醇抗發炎藥（NSAIDs）領域的競爭格局依然有利於那些擁有可靠供應鏈、清晰的安全訊息和針對性臨床差異化優勢的公司。領先的製藥公司正在透過拓展劑型、探索新型給藥途徑以及投資上市後安全性測試來最佳化其生命週期策略，從而增強醫生和患者的信心。此外，一些公司正利用與專業生產商和合約開發組織（CDO）的合作關係，縮短高附加價值製劑的上市時間，降低資本密集度，並利用其在經皮和外用製劑平台方面的技術專長。

為產業領導者提供可操作的策略重點和營運措施，以降低風險、增強差異化並加速商業性績效。

產業領導企業應採取果斷行動，透過有針對性的投資和營運最佳化，將不斷變化的市場趨勢轉化為競爭優勢。優先考慮原料和成品來源多元化，以降低關稅和地緣政治風險，同時實施先進的情境規劃，量化供應中斷對營運的影響。加強藥物安全檢測和真實世界數據（REW）收集項目，以支持安全性評估，並促進與監管機構、支付方和配藥醫生的建設性對話。

透明且可重複的調查方法，結合關鍵相關人員的訪談和第二手資料的整合，提供了可靠的見解。

本分析所依據的研究結合了對不同相關人員的結構化一手訪談和嚴謹的二手資料研究，後者涵蓋了提交給公共監管機構的文件、臨床文獻和行業出版物。一手訪談透過與臨床醫生、製劑決策者、採購經理和供應鏈高管的討論，確定了影響產品採納和採購的實際挑戰和決策標準。二級資訊來源用於檢驗製劑行為趨勢、監管動態和分銷創新，並對一手訪談的見解進行三角驗證。

策略結論強調了營運韌性、基於證據的差異化和通路合作對於保持競爭優勢的重要性。

總之，受監管機構對安全性的重視、醫療服務模式的轉變以及供應鏈重組的影響，非類固醇抗發炎藥（NSAIDs）市場正經歷漸進式的演變，而非快速的變革。製造商和銷售團隊必須透過嚴謹的產品組合管理、有針對性的製劑創新以及加強與支付方和分銷合作夥伴的協作來應對這些變化。相關人員將價格敏感性納入採購計劃、投資於真實世界安全性證據並推行以患者為中心的服務模式的利益相關者，更有可能保持其市場地位並滿足臨床醫生和消費者的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章非類固醇消炎劑市場：依藥物類別分類

  • 乙酸衍生物
    • 雙氯芬酸鈉
    • Ketorolac
  • Phenamate系列
    • 氟苯那敏酸
    • 甲芬那酸
  • Oxycam系統
    • Piroxicam
    • 替諾昔康
  • 丙酸衍生物
    • 氟比洛芬
    • Ibuprofen
    • 酮洛芬
    • 萘普生
  • 水楊酸
    • 阿斯匹靈
    • 二氟尼柳
  • 選擇性COX-2抑制劑（昔布類藥物）
    • 塞來昔布
    • 依曲昔布

第9章非類固醇消炎劑市場：依劑型分類

  • 膠囊
  • 乳霜/凝膠
  • 粉末
  • 藥片

第10章：非類固醇消炎劑市場：依給藥途徑分類

  • 口服
  • 注射
  • 外用

第11章非類固醇消炎劑市場：依處方狀態分類

  • 非處方藥
  • 僅限處方箋

第12章非類固醇消炎劑市場：依上市劑型分類

  • 立即發布
  • 緩釋
    • 控釋
    • 延遲釋放/腸溶包衣
    • 緩釋

第13章非類固醇消炎劑市場：依患者群體細分

  • 成人
  • 老年人
  • 兒童

第14章非類固醇消炎劑市場：依適應症分類

  • 急性疼痛
    • 牙痛
    • 肌肉骨骼損傷（扭傷/肌肉拉傷）
    • 術後疼痛
  • 僵直性脊椎炎
  • 月經疼痛
  • 發燒/高燒
  • 偏頭痛和頭痛
  • 眼痛和炎症
  • 骨關節炎
  • 類風濕性關節炎

第15章非類固醇消炎劑市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 專科診所

第16章非類固醇消炎劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第17章非類固醇消炎劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章非類固醇消炎劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章非類固醇消炎劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章：美國非類固醇消炎劑市場

第21章：中國非類固醇消炎劑市場

第22章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbvie, Inc
  • Algen Healthcare Ltd.
  • Allegiant Health
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Arcutis BIoTherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Clearsynth Labs Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EMS SA
  • Genentech, Inc.（F. Hoffmann-La Roche AG）
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Pharbest Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Spectrum Chemical Mfg. Corp.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teikoku Seiyaku Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma plc
  • Viatris Inc.
Product Code: MRR-7C50F2739687

The Non-steroidal Anti-inflammatory Drugs Market was valued at USD 24.62 billion in 2025 and is projected to grow to USD 26.22 billion in 2026, with a CAGR of 6.71%, reaching USD 38.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.62 billion
Estimated Year [2026] USD 26.22 billion
Forecast Year [2032] USD 38.81 billion
CAGR (%) 6.71%

A clear and authoritative introduction to the current dynamics influencing clinical use, distribution, and lifecycle management of non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) continue to occupy a central role in clinical practice and consumer self-care, driven by a persistent global burden of pain, inflammation, and chronic musculoskeletal conditions. This introduction frames the evolving context in which NSAIDs operate, highlighting how patient expectations, regulatory scrutiny, and supply chain pressures intersect to reshape product development and distribution dynamics.

Over the past several years, clinicians and patients have grown more discerning about safety profiles, long-term tolerability, and the therapeutic trade-offs between efficacy and adverse effects. Concurrently, digital health platforms and pharmacy retail innovations have broadened access pathways and altered purchasing patterns. In turn, manufacturers and healthcare providers must balance evidence-based therapeutic selection with pragmatic considerations such as formulary positioning, reimbursement trends, and real-world adherence. As a result, stakeholders across the value chain are rethinking clinical messaging, lifecycle management, and distribution strategies to meet shifting demand while maintaining compliance and quality standards.

How technological advances, regulatory evolution, and shifting patient expectations are reshaping competitive strategies and product innovation in the NSAID arena

The landscape for non-steroidal anti-inflammatory drugs is undergoing transformative shifts driven by technology, regulatory evolution, and changes in patient behavior. Emerging digital therapeutics and telemedicine have altered the points of care and decision-making, creating new touchpoints for education and prescription management. At the same time, advances in pharmacovigilance and real-world evidence collection are elevating safety assessment and informing label updates and prescribing guidelines.

Manufacturers are responding by prioritizing differentiated formulations, refining pharmacokinetic profiles, and investing in patient-centric packaging and adherence solutions. In parallel, payers and procurement organizations are demanding clearer value propositions, which increasingly emphasize total cost of care and outcomes rather than unit price alone. Moreover, supply chain diversification and onshoring initiatives are prompting strategic supplier relationships and inventory optimization. Taken together, these forces are reshaping competitive positioning and accelerating innovation across formulation, route of administration, and channel strategies.

Assessing the operational and strategic repercussions of cumulative tariff adjustments on supply chain sourcing, cost management, and commercial positioning in the US context

In 2025, cumulative tariff adjustments within the United States introduced material cost pressures across pharmaceutical supply chains, influencing sourcing decisions, pricing strategies, and operational resilience. Tariff-related cost increases can cascade through the value chain, prompting manufacturers and distributors to reassess supplier footprints, negotiate revised supplier agreements, and explore alternative raw material sources to preserve margins and supply continuity.

Consequently, organizations have pursued a mix of tactics, including consolidating suppliers with robust compliance track records, accelerating qualification of secondary suppliers, and evaluating regional manufacturing capacities to reduce exposure to cross-border duties. These adjustments have prompted magnified focus on total landed cost models and inventory planning to buffer volatility. At the same time, commercial teams have intensified dialogue with payers and major purchasers to articulate cost drivers and value differentiators that justify pricing adjustments. Looking forward, firms that integrate tariff sensitivity into strategic procurement and scenario planning will be better positioned to maintain product availability while safeguarding financial performance.

Segment-driven insights that connect distribution channel, administration route, drug class, formulation types, and end-user dynamics to strategic decision points

A nuanced segmentation framework reveals where clinical preferences, channel economics, and formulation choices intersect to influence product viability and adoption. Based on Distribution Channel, the market is studied across Over The Counter and Prescription, highlighting divergent demand drivers where consumer self-care priorities shape OTC traction while clinical guidelines and reimbursement determine prescription utilization. Based on Route Of Administration, the market is studied across Oral, Parenteral, and Topical, underscoring how administration mode influences safety monitoring, patient adherence, and formulation development priorities.

Based on Drug Class, the market is studied across COX-2 Inhibitors and Nonselective COX Inhibitors, reflecting distinct efficacy and safety trade-offs that inform therapeutic positioning and regulatory scrutiny. Based on Formulation, the market is studied across Capsules, Creams, Gels, Powders, Suspensions, Tablets, and Transdermal Patches, each of which carries unique manufacturing, stability, and patient-preference implications. Based on End User, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, demonstrating how procurement cycles, dispensing protocols, and patient access differ by channel. Integrating these segmentation lenses reveals clear vectors for differentiation in R&D investment, marketing focus, and supply chain design, and it clarifies the levers that drive product uptake and clinical acceptance across diverse care settings.

Regional intelligence explaining how distinct regulatory frameworks, payer dynamics, and care models drive differentiated strategies across global geographies

Regional dynamics continue to shape regulatory approaches, reimbursement pathways, and adoption patterns for non-steroidal anti-inflammatory therapies, and a regionally attuned strategy is essential for commercial success. In the Americas, stakeholders navigate a complex interplay of payer-driven access controls, consolidated distribution networks, and high rates of consumer engagement with OTC analgesics, requiring tailored evidence generation and value communication. In Europe, Middle East & Africa, regulatory frameworks and healthcare financing models vary markedly across jurisdictions, which drives differentiated product registration strategies and localized evidence packages to meet heterogeneous standards and procurement processes.

In the Asia-Pacific region, demographic shifts toward aging populations, expanding primary care infrastructure, and strong growth in e-pharmacy adoption are converging to increase demand for both prescription and OTC NSAID formulations. Across all regions, local manufacturing capabilities, regulatory timelines, and supply chain resilience inform launch sequencing and portfolio prioritization. Therefore, commercial teams must align regional market access strategies with local clinical practice patterns and distribution realities, and they must invest in regulatory intelligence and stakeholder engagement to accelerate adoption while maintaining compliance.

Company-level strategies that prioritize supply reliability, product differentiation, and evidence-driven positioning to strengthen competitive advantage

Competitive dynamics in the NSAID space continue to favor organizations that combine reliable supply chains, clear safety messaging, and targeted clinical differentiation. Leading pharmaceutical companies are refining lifecycle strategies by extending formulations, pursuing novel delivery mechanisms, and investing in post-marketing safety studies that reinforce confidence among prescribers and patients. In addition, several firms are leveraging partnerships with specialty manufacturers and contract development organizations to accelerate time-to-market for value-added formulations, reduce capital intensity, and access technical expertise in transdermal and topical platforms.

Strategic alliances between branded manufacturers and retail or online pharmacy chains are becoming more prevalent to secure shelf placement and consumer visibility. At the same time, product stewardship and pharmacovigilance investments have become non-negotiable differentiators, particularly as regulators and payers demand robust real-world evidence to support ongoing approvals and label updates. Firms that demonstrate operational excellence, transparent safety data, and coherent value narratives will maintain stronger relationships with payers, clinicians, and distribution partners, and they will be better positioned to defend and extend commercial relevance.

Actionable strategic priorities and operational levers for industry leaders to mitigate risk, strengthen differentiation, and accelerate commercial performance

Industry leaders should act decisively to translate evolving dynamics into competitive advantage through targeted investments and operational refinement. Prioritize diversification of raw material and finished-goods sourcing to mitigate tariff exposure and geopolitical risk, and concurrently implement advanced scenario planning that quantifies the operational impact of supply disruptions. Enhance pharmacovigilance and real-world evidence generation programs to support safety narratives and to facilitate constructive engagement with regulators, payers, and prescribers.

Furthermore, accelerate investments in differentiated formulations and patient-centric delivery systems that address adherence challenges and unmet needs, and align commercial messaging to emphasize total therapeutic value rather than unit price. Strengthen partnerships with distribution channels-hospital systems, retail pharmacies, and online pharmacies-to secure preferred placement and to tailor promotional tactics to channel-specific buying behavior. Finally, embed sustainability and quality assurance into supplier selection and manufacturing practices to meet rising stakeholder expectations and to reduce long-term operational risk.

A transparent and reproducible research methodology combining primary stakeholder interviews and secondary evidence synthesis to support robust insights

The research underpinning this analysis combined structured primary interviews with a cross-section of stakeholders and rigorous secondary research across public regulatory filings, clinical literature, and industry publications. Primary engagements included discussions with clinicians, formulary decision-makers, procurement leads, and supply chain executives to surface practical challenges and decision criteria that influence adoption and procurement. Secondary sources were used to validate trends in prescribing behavior, regulatory updates, and distribution innovations, and to triangulate findings from primary interviews.

Analytical approaches included thematic synthesis of qualitative inputs, scenario-based supply chain modeling to assess tariff impacts, and comparative assessment of formulation and channel dynamics. Quality assurance processes involved cross-validation of key assertions with multiple sources and iterative review by subject-matter experts. This methodology ensured that strategic conclusions reflect real-world stakeholder priorities and that recommended actions are grounded in defensible evidence and operational feasibility.

Strategic conclusion emphasizing operational resilience, evidence-based differentiation, and aligned channel engagement to sustain competitive relevance

In conclusion, the NSAID landscape is in a period of pragmatic evolution rather than radical upheaval, with incremental shifts driven by regulatory emphasis on safety, changing care delivery models, and supply chain realignment. Manufacturers and commercial teams must navigate these changes with disciplined portfolio management, targeted formulation innovation, and enhanced engagement with payers and distribution partners. Stakeholders that integrate tariff sensitivity into procurement planning, invest in real-world safety evidence, and pursue patient-centric delivery formats will be better positioned to sustain relevance and meet clinician and consumer needs.

Moving forward, organizations should maintain a dual focus on near-term operational resilience and medium-term clinical differentiation. By harmonizing supply chain decisions with evidence generation and channel strategies, firms can reduce exposure to external shocks while creating durable competitive advantages. Ultimately, the most successful players will combine operational rigor with a clear articulation of clinical and economic value to secure trust among clinicians, payers, and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class

  • 8.1. Acetic Acid Derivatives
    • 8.1.1. Diclofenac
    • 8.1.2. Ketorolac
  • 8.2. Fenamates
    • 8.2.1. Flufenamic Acid
    • 8.2.2. Mefenamic Acid
  • 8.3. Oxicams
    • 8.3.1. Piroxicam
    • 8.3.2. Tenoxicam
  • 8.4. Propionic Acid Derivatives
    • 8.4.1. Flurbiprofen
    • 8.4.2. Ibuprofen
    • 8.4.3. Ketoprofen
    • 8.4.4. Naproxen
  • 8.5. Salicylates
    • 8.5.1. Aspirin
    • 8.5.2. Diflunisal
  • 8.6. Selective COX-2 Inhibitors (Coxibs)
    • 8.6.1. Celecoxib
    • 8.6.2. Etoricoxib

9. Non-steroidal Anti-inflammatory Drugs Market, by Formulation

  • 9.1. Capsules
  • 9.2. Creams/Gels
  • 9.3. Powders
  • 9.4. Tablets

10. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status

  • 11.1. Over-The-Counter
  • 11.2. Prescription Only

12. Non-steroidal Anti-inflammatory Drugs Market, by Release Type

  • 12.1. Immediate-Release
  • 12.2. Modified-Release
    • 12.2.1. Controlled-Release
    • 12.2.2. Delayed-Release/Enteric-Coated
    • 12.2.3. Extended-Release

13. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

  • 13.1. Adults
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Non-steroidal Anti-inflammatory Drugs Market, by Indication

  • 14.1. Acute Pain
    • 14.1.1. Dental Pain
    • 14.1.2. Musculoskeletal Injury (Sprain/Strain)
    • 14.1.3. Postoperative Pain
  • 14.2. Ankylosing Spondylitis
  • 14.3. Dysmenorrhea
  • 14.4. Fever/Pyrexia
  • 14.5. Migraine & Headache
  • 14.6. Ophthalmic Pain & Inflammation
  • 14.7. Osteoarthritis
  • 14.8. Rheumatoid Arthritis

15. Non-steroidal Anti-inflammatory Drugs Market, by End User

  • 15.1. Ambulatory Surgical Centers
  • 15.2. Homecare
  • 15.3. Hospitals
  • 15.4. Specialty Clinics

16. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

  • 16.1. Hospital Pharmacies
  • 16.2. Online Pharmacies
  • 16.3. Retail Pharmacies

17. Non-steroidal Anti-inflammatory Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Non-steroidal Anti-inflammatory Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Non-steroidal Anti-inflammatory Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Non-steroidal Anti-inflammatory Drugs Market

21. China Non-steroidal Anti-inflammatory Drugs Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbvie, Inc
  • 22.6. Algen Healthcare Ltd.
  • 22.7. Allegiant Health
  • 22.8. Amgen Inc.
  • 22.9. Amneal Pharmaceuticals LLC
  • 22.10. Arcutis Biotherapeutics, Inc.
  • 22.11. Astellas Pharma Inc.
  • 22.12. AstraZeneca PLC
  • 22.13. BASF SE
  • 22.14. Bayer AG
  • 22.15. Boehringer Ingelheim GmbH
  • 22.16. Bristol-Myers Squibb Company
  • 22.17. Clearsynth Labs Limited
  • 22.18. Daiichi Sankyo Company, Limited
  • 22.19. Dr. Reddy's Laboratories Ltd.
  • 22.20. Eisai Co., Ltd.
  • 22.21. Eli Lilly and Company
  • 22.22. EMS S.A.
  • 22.23. Genentech, Inc. by F. Hoffmann-La Roche AG
  • 22.24. Gilead Sciences, Inc.
  • 22.25. GlaxoSmithKline PLC
  • 22.26. Hikma Pharmaceuticals PLC
  • 22.27. Incyte Corporation
  • 22.28. Johnson & Johnson Services, Inc.
  • 22.29. Merck KGaA
  • 22.30. Novartis AG
  • 22.31. Pfizer Inc.
  • 22.32. Pharbest Pharmaceuticals, Inc.
  • 22.33. Sandoz International GmbH
  • 22.34. Sanofi S.A.
  • 22.35. Spectrum Chemical Mfg. Corp.
  • 22.36. Sun Pharmaceutical Industries Ltd.
  • 22.37. Takeda Pharmaceutical Co. Ltd.
  • 22.38. Teikoku Seiyaku Co., Ltd.
  • 22.39. Teva Pharmaceutical Industries Ltd.
  • 22.40. Verona Pharma plc
  • 22.41. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)

T